Key result
Vamorolone prevents cardiomyopathy progression with improved safety over prednisolone in dystrophic mice.
Why the study?
Cardiomyopathy is a leading cause of death in Duchenne muscular dystrophy, where mineralocorticoid and glucocorticoid receptors play distinct roles in dystrophic heart and skeletal muscle pathophysiology.
Does vamorolone prevent inflammation and dystrophic cardiomyopathy in Duchenne muscular dystrophy models?
Does vamorolone prevent inflammation and dystrophic cardiomyopathy in Duchenne muscular dystrophy models?
Vamorolone acts as a dual MR antagonist and dissociative GR ligand, offering a potentially safer and more effective treatment for inflammation and cardiomyopathy in Duchenne muscular dystrophy compared to traditional corticosteroids.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for vamorolone in DMD cardiomyopathy; human trials needed before any clinical consideration.
Cardiomyopathy is a leading cause of death for Duchenne muscular dystrophy. Here, we find that the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) can share common ligands but play distinct roles in dystrophic heart and skeletal muscle pathophysiology. Comparisons of their ligand structures indicate that the Δ9,11 modification of the first-in-class drug vamorolone enables it to avoid interaction with a conserved receptor residue (N770/N564), which would otherwise activate transcription factor properties of both receptors. Reporter assays show that vamorolone and eplerenone are MR antagonists, whereas prednisolone is an MR agonist. Macrophages, cardiomyocytes, and CRISPR knockout myoblasts show vamorolone is also a dissociative GR ligand that inhibits inflammation with improved safety over prednisone and GR-specific deflazacort. In mice, hyperaldosteronism activates MR-driven hypertension and kidney phenotypes. We find that genetic dystrophin loss provides a second hit for MR-mediated cardiomyopathy in Duchenne muscular dystrophy model mice, as aldosterone worsens fibrosis, mass and dysfunction phenotypes. Vamorolone successfully prevents MR-activated phenotypes, whereas prednisolone activates negative MR and GR effects. In conclusion, vamorolone targets dual nuclear receptors to treat inflammation and cardiomyopathy with improved safety.
No takes yet. Share an insight, caveat, or question.
Heier et al. (2019) studied Duchenne muscular dystrophy (DMD) cardiomyopathy. Vamorolone vs. Vehicle, Prednisolone, Eplerenone, Spironolactone was evaluated on Heart function (fractional shortening) and fibrosis (p=<0.0005). Vamorolone acts as a dual mineralocorticoid receptor antagonist and dissociative glucocorticoid receptor ligand to prevent cardiomyopathy progression and inhibit inflammation with improved safety over prednisolone in dystrophic mice.
Synapse has enriched 10 related papers. Consider them for comparative context: